{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T21:35:12Z","timestamp":1778448912090,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.jpsychires.2014.09.013","type":"journal-article","created":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T12:36:30Z","timestamp":1411216590000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: Systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"60","author":[{"given":"Chittaranjan","family":"Andrade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Kisely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-0965","authenticated-orcid":false,"given":"Ingrid","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2014.09.013_bib1","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.4088\/JCP.12f07977","article-title":"Modafinil and armodafinil in schizophrenia","volume":"73","author":"Andrade","year":"2012","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-011-2513-z","article-title":"A\u00a0placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia","volume":"220","author":"Arbabi","year":"2012","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.schres.2011.05.015","article-title":"The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia\/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial","volume":"130","author":"Bobo","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","article-title":"Persistent negative symptoms in schizophrenia: an overview","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/NDT.S43404","article-title":"Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options","volume":"10","author":"Chue","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib6","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1097\/00001756-200111160-00032","article-title":"Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats","volume":"12","author":"de Saint Hilaire","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neuroscience.2013.07.071","article-title":"Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation","volume":"252","author":"Federici","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib8","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.08m04683","article-title":"Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial","volume":"70","author":"Freudenreich","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11920-010-0148-0","article-title":"Assessment of pharmacotherapy for negative symptoms of schizophrenia","volume":"12","author":"Hanson","year":"2010","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib10","series-title":"Cochrane Handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]","year":"2011"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib11","series-title":"New Oxford textbook of psychiatry","first-page":"540","article-title":"Epidemiology of schizophrenia","author":"Jablensky","year":"2009"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2011.11.006","article-title":"Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study","volume":"135","author":"Kane","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4088\/JCP.09m05950gry","article-title":"Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study","volume":"71","author":"Kane","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jpsychires.2013.04.013","article-title":"NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials","volume":"47","author":"Kishi","year":"2013","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12017-013-8251-0","article-title":"Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review","volume":"16","author":"Kishi","year":"2014","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/070674371405900103","article-title":"Neurocognition: clinical and functional outcomes in schizophrenia","volume":"59","author":"Lepage","year":"2014","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2013.03.019","article-title":"A\u00a0systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities","volume":"147","author":"Lindenmayer","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.schres.2013.07.039","article-title":"Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study","volume":"150","author":"Lohr","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.schres.2013.07.058","article-title":"Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia","volume":"150","author":"Marder","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2165\/00023210-200418130-00007","article-title":"Amisulpride: a review of its use in the management of schizophrenia","volume":"18","author":"McKeage","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-013-3232-4","article-title":"The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders","volume":"229","author":"Mereu","year":"2013","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jpsychires.2014.03.021","article-title":"Humanistic burden in schizophrenia: a literature review","volume":"54C","author":"Millier","year":"2014","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib23","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.npp.1301534","article-title":"Modafinil: a review of neurochemical actions and effects on cognition","volume":"33","author":"Minzenberg","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib24","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2006.07.002","article-title":"Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review","volume":"88","author":"Murphy","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1358\/dot.2008.44.5.1195861","article-title":"Armodafinil for excessive daytime sleepiness","volume":"44","author":"Nishino","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4088\/JCP.v68n0507","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia","volume":"68","author":"Pierre","year":"2007","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neuropharm.2012.07.011","article-title":"Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain","volume":"64","author":"Scoriels","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4088\/JCP.v66n0705","article-title":"Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications","volume":"66","author":"Sevy","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.schres.2010.08.007","article-title":"Cognitive and symptomatic predictors of functional disability in schizophrenia","volume":"126","author":"Shamsi","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bdi.12026","article-title":"Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review","volume":"15","author":"Sienaert","year":"2013","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/bjp.bp.109.067710","article-title":"Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis","volume":"197","author":"Singh","year":"2010","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib33","first-page":"297","article-title":"Effect of anticholinergics on positive and negative symptoms in schizophrenia","volume":"28","author":"Tandon","year":"1992","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib34","first-page":"495","article-title":"Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998","volume":"44","author":"Tsang","year":"2010","journal-title":"Aust N. Z J Psychiatry"},{"key":"10.1016\/j.jpsychires.2014.09.013_bib35","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jama.2009.351","article-title":"Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications","volume":"301","author":"Volkow","year":"2009","journal-title":"JAMA"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395614002805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395614002805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:10:13Z","timestamp":1758366613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395614002805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":35,"alternative-id":["S0022395614002805"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2014.09.013","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: Systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2014.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}